New combo therapy and advanced scans aim to improve prostate cancer detection and treatment
NCT ID NCT03860987
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 39 times
Summary
This study tested a combination of three hormone-blocking drugs (enzalutamide, abiraterone, and standard hormone therapy) given before surgery in 12 men with newly diagnosed prostate cancer that hasn't spread. Researchers also used special PET/CT scans with a new tracer to see if they could better detect and track the cancer. The goal was to improve treatment and imaging, but men still needed surgery and long-term follow-up, so this is about controlling the disease, not curing it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATE-SENSITIVE PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.